# Schedules of Controlled Substances: Placement of Centanafadine in Schedule III

**Action Urgency Score:** 65/100

| Field | Value |
|---|---|
| Agency | Justice Department; Drug Enforcement Administration |
| Type | Final rule |
| Action | Interim final rule; request for comments. |
| Published | 2026-10-30 |
| Effective | 2026-10-30 |
| Comments close | 2026-11-30 |
| Significant | No |
| CFR parts | 21 CFR 1308 |
| Summary | On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder in adults and pediatric patients aged 6 years and older, weighing at least 20 kg. The Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place centanafadine, chemically known as (1R,5S)-1- (naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in schedule III of the Controlled Substances Act (CSA). In accordance with the CSA, as amended b |
| Document number | 2026-22208 |

## Why this score
- Comment deadline within 30 days.
- Final rule.

Source: Federal Register API (Office of the Federal Register) (https://www.federalregister.gov/documents/2026/10/30/2026-22208/schedules-of-controlled-substances-placement-of-centanafadine-in-schedule-iii). Last refreshed: 2026-11-04T21:40:49.974Z.
Data from the Federal Register API; the published Federal Register document is authoritative. Informational only, not legal advice.